Document is current
Any future updates will be listed below
-
Authors
Mori, Tim https://orcid.org/0009-0000-8363-7434
Prystupa, Katsiaryna https://orcid.org/0000-0003-3368-1028
Straßburger, Klaus https://orcid.org/0000-0002-6636-1373
Bonn, Marc
Zaharia, Oana Patricia https://orcid.org/0000-0002-5738-9585
Spörkel, Olaf
Kuß, Oliver https://orcid.org/0000-0003-3301-5869
Roden, Michael https://orcid.org/0000-0001-8200-6382
Wagner, Robert https://orcid.org/0000-0002-6120-0191
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 13 December 2024
First Online: 17 January 2025
Declarations
:
: RW reports lecture fees from Novo Nordisk, Sanofi-Aventis, Boehringer-Ingelheim and Eli Lilly and served on the advisory board for Akcea Therapeutics, Daiichi Sankyo, Sanofi-Aventis, Eli Lilly and NovoNordisk. M.R. received fees for consulting or lecturing from Astra Zeneca, Boehringer- Ingelheim, Echosens, Eli Lilly, Madrigal Pharmaceuticals, MSD Sharp & Dohme, Novo Nordisk and Pfizer and performed investigator-initiated research with support from Boehringer Ingelheim, Danone Nutricia Research and Novo Nordisk. KP reports lecture fees from Berlin-Chemie. OK, OS, OPZ, MB, KS and TM report no conflicts of interest.
